Metropolitan Life Insurance Company (MetLife)’s Phathom Pharmaceuticals PHAT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,818	Closed	-$19.3K	–	1548
2024 Q1	$19.3K	Hold	1,818	–	–	﹤0.01%	1880
2023 Q4	$16.6K	Hold	1,818	–	–	﹤0.01%	1994
2023 Q3	$18.9K	Buy	1,818 +445	+32%	+$6.1K	﹤0.01%	1929
2023 Q2	$19.7K	Hold	1,373	–	–	﹤0.01%	1941
2023 Q1	$9.8K	Sell	1,373 -29	-2%	-$255	﹤0.01%	2165
2022 Q4	$15.7K	Hold	1,402	–	–	﹤0.01%	2119
2022 Q3	$15.5K	Hold	1,402	–	–	﹤0.01%	2141
2022 Q2	$11.8K	Hold	1,402	–	–	﹤0.01%	2279
2022 Q1	$19.1K	Sell	1,402 -4,540	-76%	-$73.3K	﹤0.01%	2120
2021 Q4	$117K	Hold	5,942	–	–	﹤0.01%	2381
2021 Q3	$191K	Hold	5,942	–	–	﹤0.01%	2112
2021 Q2	$201K	Buy	5,942 +2,355	+66%	+$84.3K	﹤0.01%	2139
2021 Q1	$135K	Hold	3,587	–	–	﹤0.01%	2277
2020 Q4	$119K	Hold	3,587	–	–	﹤0.01%	2265
2020 Q3	$132K	Hold	3,587	–	–	﹤0.01%	2057
2020 Q2	$118K	Hold	3,587	–	–	﹤0.01%	2151
2020 Q1	$92.6K	Buy	+3,587	New	+$120K	﹤0.01%	2074

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PHAT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Phathom Pharmaceuticals (PHAT) in Q2 2024, closing a stake of 1,818 shares — an estimated $19.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PHAT in Q1 2020 and held it in 17 quarters. The position peaked at $201K in Q2 2021. 114 funds tracked by Wall St. Rank hold PHAT as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Phathom Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,818 Phathom Pharmaceuticals shares in Q2 2024, an estimated $19.3K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Phathom Pharmaceuticals in Q1 2020 and held it in 17 quarters.
Metropolitan Life Insurance Company (MetLife)'s Phathom Pharmaceuticals position peaked at $201K in Q2 2021.
114 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.